Últimas noticias sobre Immuron (NASDAQ:IMRN) Bolsa

Immuron

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron Limited - American Depositary Shares

Immuron Ltd

Stryker (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) is a medical device company that has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry. The company has often acquired other firms to boost its competitiveness and add capabilities. Still, recent months in 2024 have been particularly active for Stryker when it comes to acquisitions.
Since the beginning of July, the company has closed on or announced purchases of five companies. I&#39;ll dive into what Stryker does and the most important of these acquisitions to help determine whether they make the stock a buy.
<h2>Stryker: A Highly Diversified Medical Device Company</h2>
Stryker has two reportable segments: MedSurg &amp; Neurotechnology and Orthopedics &amp; Spine. MedSurg provides surgical tools, including minimally invasive devices. These include small cameras used in surgeries. Neurotechnology offers tools for skull and brain surgeries, including stroke treatments. In 2023, this segment accounted for 58% of the company&#39;s total revenue.
The other segment revolves around bodily implants. Orthopedics includes hip, knee, and shoulder implants to replace these joints. The company&#39;s Mako system provides robotics-assisted replacement of these joints. It has similarities to Intuitive Surgical&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) da Vinci system, but the two specialize in different treatment areas.
This segment also provides trauma and extremity implants. Trauma refers to implants used to help repair large broken bones like those in the arms and legs. Extremity implants help repair joints and bones in the hands and feet. It also provides spinal implants. This segment accounted for 42% of revenue in 2023.
<h2>Breaking Down Stryker&#39;s Recent Acquisitions</h2>
I&#39;ll focus on two of Stryker&#39;s recent acquisitions, NICO and Care.ai.
The NICO acquisition now gives Stryker ownership of minimally invasive devices that are used to surgically treat intracerebral hemorrhage (ICH). ICH is the deadliest form of stroke and affects 3.4 million people annually. The current care standard for ICH is medical management. This means doctors keep the patient stable while they hope the body can remove the blood clot over time.
The New England Journal of Medicine published a study where the NICO technology cut patient mortality rates by nearly in half compared to medical management. Additionally, the patients treated using NICO had significantly better quality of life outcomes. Given the large number of patients who suffer from ICH and the impressive efficacy of NICO technology, this feels like a strong purchase.
The care.ai purchase allows Stryker to offer its hospital and health provider customers tools to more efficiently monitor the status of patients. This allows these customers to make better decisions about how to allocate resources across patients. For example, patients can use AI chatbots to assess their condition. They can check whether they need urgent medical care or not.
The company&#39;s technology can also improve the monitoring of patients while they are in the healthcare facility. Its &quot;smart room&quot; technology involves installing sensors that use AI to better monitor the condition of patients. These features can help Stryker&#39;s customers better prioritize staff and resources in a facility. They aim to improve patient outcomes and satisfaction.
Overall, this could create value for Stryker customers. However, I am less sold on it compared to NICO. Just because a company uses AI in its offerings doesn&#39;t mean it is truly providing differentiated value compared to what already exists.
In the near term, these acquisitions will not impact the company&#39;s financial results. This is likely the case, as the financial details of these acquisitions were not disclosed. The Securities and Exchange Commission (SEC) does not require publicly traded companies to disclose these details unless the acquisitions are expected to have a material impact on the company&#39;s financial statements. Still, they could definitely create value for the company over the long term.
I especially like the NICO acquisition, and it could be a good thing that the company did not have to disclose the price. It might suggest that they were able to acquire the asset at a reasonable cost.
<h2>Stryker Is Expected to See Robust Earnings Growth</h2>
Analysts expect strong earnings growth over the next two years, especially versus its peers. Analysts expect a 12% annual growth in trailing twelve months earnings per share. That is over double the rate of one of its main competitors, Medtronic (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>).
Two Wall Street analysts raised their price target for Stryker in October. Their average price target implies an upside of 7% for the stock. Stryker remains a strong player in its industry, but these acquisitions don&#39;t move the needle on the stock for me right now.
The article &quot;<a href="https://www.marketbeat.com/originals/strykers-acquisition-spree-double-digit-growth-on-the-horizon/">Stryker&#39;s Acquisition Spree: Double-Digit Growth on the Horizon</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

News

Price Target

Offerings

Markets

Analyst Ratings

Trading Ideas

ISRG

Stryker's Acquisition Spree: Double-Digit Growth on the Horizon

Vice President Kamala Harris' campaign received $1 million in XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) from <a href="https://www.benzinga.com/content/40757553/ripple-co-founder-chris-larsen-endorses-kamala-harris-for-president-cnbc">Ripple co-founder Chris Larsen</a>.
What Happened: Federal Election Commission (FEC) <a href="https://www.fec.gov/data/receipts/individual-contributions/?contributor_name=chris+larsen&amp;two_year_transaction_period=2024&amp;min_date=01%2F01%2F2023&amp;max_date=12%2F31%2F2024">filings</a> show Larsen donated $1 million in XRP crypto coin (in kind 1.7 million XRP) to Future Forward USA PAC on Aug. 14. The political action committee supports Harris and her campaign.
So far, Larsen <a href="https://x.com/Cointelegraph/status/1844791319257911411">donated</a> $1.9 million to Harris as he endorses her in the 2024 White House race. In early September, he signed a letter which favors a <a href="https://www.benzinga.com/news/24/09/40749774/kamala-harris-receives-backing-from-88-corporate-leaders-in-presidential-bid-against-trump-report">Democratic administration under Harris</a>. The letter stated that Harris would &#8220;continue to advance fair and predictable policies that support the rule of law, stability, and a sound business environment.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f1fa;&#x1f1f8; JUST IN: Ripple founder donates $1 million in <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> to Kamala Harris. <a href="https://t.co/LYtG1m0BPX">pic.twitter.com/LYtG1m0BPX</a>
&mdash; Cointelegraph (@Cointelegraph) <a href="https://twitter.com/Cointelegraph/status/1844791319257911411?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On the other hand, Ripple is in an ongoing legal spat <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39667693/crypto-regulation-sparks-legal-spats-ripple-sec-and-pending-s-1-approvals-in-focus">with SEC Chair Gary Gensler</a> over whether the XRP digital token should be<a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35340802/sec-asks-judge-to-dismiss-lawsuit-against-ripple-executives-but-theres-pending-issues" target="_blank" rel="noreferrer noopener"> </a>registered as a security. Both parties appealed against a final judgment given in August.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/digital-assets"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a><figcaption class="wp-element-caption">Benzinga Future of Digital Assets conference.</figcaption></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41224030/grant-cardones-thinks-kamala-harris-misses-the-mark-on-financial-literacy-if-she-is-electe">Grant Cardone&#8217;s Thinks Kamala Harris Misses The Mark On Financial Literacy: &#8216;If She Is Elected, Forget Crypto!&#8217;</a>
Why It Matters: Prediction platform Polymarket <a href="https://polymarket.com/event/presidential-election-winner-2024?tid=1728672141444">shows</a> Harris&#8217;s probability of winning the presidential election stands at 46% compared to Donald Trump's 53.6%.
In early September, it was known that Harris' <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40727168/kamala-harris-super-pac-now-accepting-bitcoin-ethereum-and-other-cryptocurrencies-for-camp">presidential campaign has started accepting cryptocurrency donations</a> and the team is in discussions with Coinbase and Ripple. &nbsp;
In a recent development, Harris indicated that she would consider any <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40972902/kamala-harris-finally-mentions-crypto-and-that-too-on-wall-street-promises-to-encourage-in">encouraging technologies like artificial intelligence and digital assets.</a>
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41284530/trump-widens-lead-over-harris-in-betting-odds-on-prediction-markets-sets-a-new-high-on-cry">Trump Widens Lead Over Harris In Betting Odds On Prediction Markets —Sets A New High On Crypto-Based Polymarket</a></li>
</ul>
Image:

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$XRP

Kamala Harris Receives $1 Million In XRP From Ripple Co-Founder Chris Larsen

A California judge has denied a temporary restraining order (TRO) filed by national hemp advocates and businesses, including <a href="https://www.benzinga.com/markets/cannabis/24/10/41196739/cheech-and-chong-cannabis-company-hemp-roundtable-petition-court-to-stop-gov-newsoms-controversi">Cheech and Chong's Global Holdings</a>, aimed at blocking the state's controversial ban on hemp products with detectable levels of THC. 
The TRO, which was requested as part of a lawsuit filed last month by the U.S. Hemp Roundtable and several hemp companies, sought to halt the enforcement of the new regulations until the case could be fully heard. 
However, the judge sided with the state and Gov. Gavin Newsom, allowing the ban to remain in place.
<h3 class="wp-block-heading">Emergency Regulations Banning Hemp</h3>
The <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">emergency regulations</a>, which went into effect on September 23, prohibit the sale of consumable hemp products with any detectable delta-9 THC or intoxicating cannabinoids like delta-8 THC in California. 
These regulations also limit hemp products to five servings per package and restrict sales to individuals aged 21 and over. 
Hemp advocates argue that this will severely impact the industry, especially businesses producing non-intoxicating hemp products that provide therapeutic benefits to consumers.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41124583/californias-new-hemp-rules-could-reshape-cannabis-a-different-set-of-rules-in-every-state">California&#8217;s New Hemp Rules Could Reshape Cannabis: &#8216;A Different Set Of Rules In Every State&#8217;</a>
<h3 class="wp-block-heading">Industry Reacts</h3>
The ruling prompted strong reactions. 
&#8220;Today, a judge sided against common sense and in favor of Gov. Newsom. The judge's ruling to deny a temporary restraining order against Newsom's hemp products ban announces that Californians will lose access to USDA-certified organic hemp products in retail stores across the state,&#8221; Jim Higdon, president of <a href="https://www.benzinga.com/markets/cannabis/24/09/40833963/expert-calls-for-a-united-hemp-and-cannabis-front-industries-should-collaborate-and-push-for-fed">Cornbread Hemp </a>and a member of the U.S. Hemp Roundtable, told Benzinga Cannabis in an email.
&#8220;At a time when the California cannabis dispensary system is undergoing a credibility crisis due to pesticide contamination, the governor has made it much more difficult for Californians to access the only cannabis products that consumers can be certain are free of pesticides – USDA-certified organic hemp products with third-party lab tests,&#8221; Higdon said.
The legal battle is set to continue, as the case moves forward, with the hemp industry determined to challenge the ban's legality in court.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a></li>
</ul>
Cover: AI Generated Image

Cannabis

Government

California Judge Rules Gov. Newsom's Hemp Ban Stands Despite Industry Pushback

As geopolitical tensions between Iran and Israel escalate, the global energy markets are once again on edge. Recent developments, including Iranian missile strikes on Tel Aviv and Israel&#39;s ground operations in southern Lebanon, have rattled investor confidence. The rising fear that the conflict in the Middle East could disrupt supply from key oil-producing nations has already triggered a surge in oil prices.
The effects of market volatility are generally more subdued for the midstream energy sector, which plays a critical role in transporting and storing oil and natural gas. These companies&#39; operational models are designed to offer stability, largely insulated from fluctuating commodity prices. In the current climate of uncertainty, midstream firms are proving their resilience by maintaining steady revenue streams through long-term contracts, even as oil prices spike.
<h2>Stability in Unstable Times</h2>
Midstream energy companies, which manage essential infrastructure like pipelines and storage facilities, typically operate under long-term &quot;take-or-pay&quot; contracts. These contracts guarantee that shippers, such as oil producers, pay for reserved capacity regardless of how much they use&nbsp;it. This framework ensures that&nbsp;midstream firms receive stable revenues, independent of short-term shifts in oil prices or demand fluctuations.
This unique model allows midstream players to secure predictable cash flows and earnings, even during market turmoil. As oil prices climb due to concerns over supply disruptions, midstream companies can benefit from increased production activity and higher throughput in their pipelines without being directly exposed to the volatility of oil prices.
<h2>Leveraging Oil Price Increases</h2>
While midstream firms are generally insulated from price swings, rising oil prices can still create growth opportunities. In particular, higher oil prices encourage producers to ramp up output, especially in the key U.S. basins like the Permian. This, in turn, drives the volumes transported by midstream companies and boosts the demand for storage services, as producers may choose to hold onto crude until prices peak.
By capitalizing on the increased production and transportation activity, midstream companies can see revenue growth through higher tariffs on their pipelines and enhanced utilization of storage assets.
<h2>Midstream Leaders: EPD, MPLX &amp; HESM</h2>
Enterprise Products Partners (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/epd#NYSE">EPD</a>): With a substantial portion of its revenues coming from long-term, fee-based contracts, EPD remains largely insulated from commodity price volatility. The company&#39;s extensive crude oil pipeline infrastructure, particularly in the Permian Basin, positions it to benefit from increased production activity as oil prices rise.
MPLX LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mplx#NYSE">MPLX</a>): Through its strong partnership with Marathon Petroleum Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpc#NYSE">MPC</a>), MPLX secures consistent revenues via long-term agreements with minimum volume commitments. This predictable income stream, combined with its expansive network of pipelines in key U.S. regions, allows MPLX to capitalize on higher oil prices through increased throughput and demand for storage services.
Hess Midstream (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hesm#NYSE">HESM</a>): Generating nearly all its revenues from long-term, fee-based contracts with Hess Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hes#NYSE">HES</a>), Hess Midstream is shielded from commodity price fluctuations. HESM&#39;s predictable income model, combined with increased production by Hess in times of higher oil prices, provides growth opportunities tied to greater volumes across its infrastructure.
<a href="https://www.zacks.com/stock/news/2349423/3-midstream-stocks-poised-to-benefit-as-geopolitical-tensions-rise?cid=CS-BENZ-FT-analyst_blog|industry_focus-2349423">To read this article on Zacks.com click here.</a>

Mid Cap

Contracts

HESM

MPLX

3 Midstream Stocks Poised to Benefit as Geopolitical Tensions Rise

'CVS to exit core infusions services business, job cuts possible' - Reuters

For the first time in three years, capital raises in the <a href="https://www.benzinga.com/cannabis">cannabis sector increased,</a> according to Frank Colombo, managing director of data analytics and investment banking at Viridian Capital Advisors. 
Colombo provided an overview of capital raising trends in the space on Tuesday at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a>. He told the crowd gathered in Chicago there's been an increase of 14.8% in capital raises in 2024, driven mostly by Canadian equities and U.S. debt.
Colombo said U.S. debt accounts for over 50% of capital raises, indicating a reliance on debt financing rather than equity in the market. Out of all sectors, retail and cultivation sectors are responsible for half of all capital raises. However, out of 12 different sectors, "investments in M&amp;A&#8221; were "really up," he said.
Colombo, along with Scott Greiper, founder and president of Viridian Capital Advisors, gave a presentation discussing the core principles of equity research and investment strategies tailored for the cannabis sector.
Colombo said the U.S. cultivation and retail sectors saw a significant 226% increase in capital raises year-to-date, primarily driven by debt refinancing rather than new capital influx. "Out of the $830 million of new debt, it&#8217;s only been like $120 of new money," he said, adding that many cannabis multi-state operators (MSOs) are overleveraged.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41237666/exclusive-tax-changes-could-unlock-hundreds-of-millions-in-cash-flow-for-cannabis-sector-experts">EXCLUSIVE: Tax Changes Could Unlock &#8216;Hundreds Of Millions In Cash Flow&#8217; For Cannabis Sector, Experts Predict</a>
<h3 class="wp-block-heading">Credit Analysis Is Of Utmost Importance</h3>
Colombo also emphasized the importance of nuanced credit analysis, recommending a laddered approach to equity investment that avoids high-risk entities while targeting those with strong credit ratings and growth potential. "You should, really, stick primarily to a company that we rate as the better credits, the top 10 out of the 30 we rate every week," Colombo said, referring to Viridian's analyses.
"For the near term, we think that the most appropriate equity stance to be in is don&#8217;t step in the proverbial dog s&#x2A;&#x2A;t," Colombo said. "Credit problems have been a big part of the equity, downturn" for a lot of cannabis operators, "so you just need to avoid disasters, and if you can do that, you&#8217;re going to get the rising of all boats."
Lastly, he said market catalysts in 2025 such as potential cannabis rescheduling and banking reform, could allow companies to improve their financial positions and attract new investments. "Pay close attention to credit analysis… As these catalysts start to happen."
That said, Greiper explained that Viridian provides insights into where capital is flowing, the types of investors involved, and how valuations are determined.
"We&#8217;re nine and a half years into this,&#8221; Greiper said. "We&#8217;ve covered about 75 billion dollars in deals and about 6500 transactions."
After joining the firm four years ago, Colombo took Viridian's work to the next level. The company continually evolves its data offerings, including a subscription model allowing historical trend analysis and deeper insights into market activity.
"We put out our market reports every day," Greiper said. &#8220;We&#8217;ve invested in our people, we&#8217;ve invested in our analysts because tracking every deal in the cannabis industry globally is really a lot of fun.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a></li>
</ul>
Frank Colombo, of Viridian Capital Advisors, speaks at the Benzinga Cannabis Capital Conference on Tuesday. Photo by Wendy Davis.

Entrepreneurship

Financing

Events

Exclusives

EXCLUSIVE: Tracking Every Cannabis Deal Is 'A Lot Of Fun,' Says Financial Expert Behind Essential Investor Tool

GigaCloud Tech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NYSE">GCT</a>) short percent of float has risen 18.12% since its last report. The company recently reported that it has 6.90 million shares sold short, which is 36.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GigaCloud Tech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728674124_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GigaCloud Tech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing GigaCloud Tech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GigaCloud Tech's peer group average for short interest as a percentage of float is 4.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About GigaCloud Tech?

Atlassian's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NYSE">TEAM</a>) short percent of float has risen 14.21% since its last report. The company recently reported that it has 3.33 million shares sold short, which is 2.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Atlassian Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728674119_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Atlassian has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Atlassian's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Atlassian's peer group average for short interest as a percentage of float is 3.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TEAM

How Is The Market Feeling About Atlassian?

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has risen 15.79% since its last report. The company recently reported that it has 6.71 million shares sold short, which is 3.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728674114_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 4.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Zimmer Biomet Holdings's Recent Short Interest

Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares are trading higher today. Here&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41257193/boeings-october-deliveries-expected-to-plummet-amid-strike-challenges-analyst">what you need to know.</a>
What To Know: A report from the U.S. Transportation Department's Office of Inspector General raised serious concerns about the FAA's oversight of Boeing's production processes. The report, commissioned by Congress, highlighted that the FAA's monitoring of Boeing's manufacturing, particularly for the 737 and 787 models, is ineffective and often reactive rather than proactive. The Office of Inspector General criticized the FAA for failing to implement a more data-driven oversight approach and pointed out unresolved safety issues. It also raised concerns about Boeing employees acting on behalf of the FAA in certain cases.
Following a fuselage panel incident on a 737 Max aircraft in January 2024, Boeing addressed safety concerns and revamped its manufacturing processes. These include internal safety reforms and new leadership, with a new CEO taking over to rebuild trust with regulators and the public. The report provided 16 recommendations for improving Boeing's compliance with FAA standards, which are set to be implemented between 2025 and 2028.
Senator Tammy Duckworth, chair of the Senate&#8217;s aviation safety subcommittee, criticized the FAA for not holding Boeing accountable and emphasized the need for stronger oversight. She pledged continued Congressional monitoring to ensure that Boeing and the FAA prioritize public safety.
Meanwhile, Boeing faces additional challenges with a four-week strike by the International Association of Machinists and Aerospace Workers, which has halted production at key facilities. The strike, involving about 33,000 workers, is expected to cost the company over $1 billion per month. Boeing has filed an unfair labor practice charge against the union, accusing it of bad faith bargaining, while the union claims Boeing is unwilling to negotiate on key issues related to wages and working conditions. The conflict remains unresolved.
Financial Metrics: The company reported a net income loss of $1.439 billion for the year, with loss EPS of $2.33. Despite revenue growth of 16.79%, Boeing continues to operate at a loss and its EBITDA margin stands at -2.40%, indicating ongoing operational difficulties. Boeing&#8217;s long-term debt is substantial at $53.162 billion and the company's enterprise value is $135.657 billion. 
BA Price Action: Boeing shares were up by 2.35% at $150.04 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-1024x537.png" alt="" class="wp-image-591869" style="width:478px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11135146/BA-1.png 1084w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41278449/why-texas-instruments-could-beat-earnings-estimates-again">Why Texas Instruments Could Beat Earnings Estimates Again</a></li>
</ul>
Photo via Shutterstock.

Movers

Boeing Company Shares Are Trading Higher Today: What's Going On

Citigroup analyst Jon Tower maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Neutral and lowers the price target from $450 to $440.

Citigroup Maintains Neutral on Domino's Pizza, Lowers Price Target to $440

Politics

General

CNN To Host Town Hall With Kamala Harris On October 23

HC Wainwright &amp; Co. analyst Edward White maintains Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) with a Buy and lowers the price target from $18 to $17.

NYXH

HC Wainwright & Co. Maintains Buy on Nyxoah, Lowers Price Target to $17

BlackRock Finance&nbsp;came out with quarterly earnings of $11.46 per share, beating the Zacks Consensus Estimate of $10.42 per share. This compares to earnings of $10.91 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 9.98%. A quarter ago, it was expected that this investment firm would post earnings of $9.96 per share when it actually produced earnings of $10.36, delivering a surprise of 4.02%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
BlackRock Finance, which belongs to the Zacks Financial - Investment Management industry, posted revenues of $5.2 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.93%. This compares to year-ago revenues of $4.52 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
BlackRock Finance shares have added about 17.7% since the beginning of the year versus the S&amp;P 500&#39;s gain of 21.2%.
<h2>What&#39;s Next for BlackRock Finance?</h2>
While BlackRock Finance has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for BlackRock Finance: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $11.14 on $5.56 billion in revenues for the coming quarter and $41.83 on $20.1 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Investment Management is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, SEI Investments (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seic#NASDAQ">SEIC</a>), has yet to report results for the quarter ended September 2024.
This investment management firm is expected to post quarterly earnings of $1.07 per share in its upcoming report, which represents a year-over-year change of +23%. The consensus EPS estimate for the quarter has been revised 2% higher over the last 30 days to the current level.
SEI Investments&#39; revenues are expected to be $532.11 million, up 11.6% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2349134/blackrock-finance-blk-surpasses-q3-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2349134">To read this article on Zacks.com click here.</a>

Earnings Beats

Management

SEIC

BlackRock Finance Surpasses Q3 Earnings and Revenue Estimates

TD Cowen analyst Doug Creutz maintains Sony Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) with a Buy, adjusts target to $23 from $107 (5-1 Stock Split).

Sony Group Corporation American Depositary Shares

SONY

TD Cowen Maintains Buy on Sony Gr, Adjusts Price Target To $23 (5-1 Stock Split)

Barclays analyst Jeffrey Bernstein maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Underweight and lowers the price target from $380 to $370.

Barclays Maintains Underweight on Domino's Pizza, Lowers Price Target to $370

Jefferies analyst Alexander Slagle maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Hold and lowers the price target from $455 to $450.

Jefferies Maintains Hold on Domino's Pizza, Lowers Price Target to $450

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Reiteration

ARWR

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target

Over the past 24 hours, Lido Staked Ether's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">STETH</a>) price has risen 3.92% to $2,444.64. This continues its positive trend over the past week where it has experienced a 1.0% gain, moving from $2,428.48 to its current price. As it stands right now, the coin's all-time high is $4,829.57. 
The chart below compares the price movement and volatility for Lido Staked Ether over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728673422_0.png" alt="price_chart" />
The trading volume for the coin has fallen 41.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has decreased 1.13%. This brings the circulating supply to 9.72 million. According to our data, the current market cap ranking for STETH is #8 at $23.76 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728673422_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$STETH

Lido Staked Ether's Price Increased More Than 3% Within 24 hours

Charles Schwab Corporation Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) shares are trading higher by 1.48% to $67.64 during Friday&#8217;s session amid strength in the <a href="https://www.benzinga.com/news/earnings/24/10/41293190/us-banks-top-q3-earnings-estimates-jpmorgan-delivers-robust-beat-financial-sector-stocks-hit-record">U.S. financial sector</a> following a series of strong third-quarter earnings reports from major institutions, including JPMorgan Chase, Wells Fargo and BlackRock.
These financial heavyweights surpassed earnings expectations, which lifted the entire sector and sparked a rally in peer financial firms like Charles Schwab.
What&#8217;s Going On: The Financial Select Sector SPDR Fund (XLF) jumped nearly 2%, hitting record highs and setting the stage for a broad-based rally across financial stocks. This momentum has had a direct impact on Schwab, with investors betting that the brokerage giant will deliver strong earnings, driven by rising interest income and solid client activity.
As a leading brokerage and wealth management firm, Charles Schwab has benefited from an ongoing shift toward self-directed investing and increasing demand for financial advice. 
In recent quarters, Schwab has also capitalized on the higher interest rate environment, which has boosted net interest margin—an area that has been a strong focus for the financial industry this earnings season. 
JPMorgan Chase, for example, beat estimates with $23.53 billion in net interest income (NII), signaling strength in this critical area of revenue generation.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41290382/producer-inflation-rises-more-than-expected-in-september-as-food-transportation-c">Producer Inflation Rises More Than Expected In September As Food, Transportation Costs Jump</a>
What Else: With interest rates remaining elevated, Schwab's NII is expected to be a key driver of its upcoming earnings. Like JPMorgan and Wells Fargo, Schwab is poised to see continued benefit from the higher rate environment as it earns interest on client cash balances held in sweep accounts. 
This could offset any potential weakness in other areas, such as asset management fees, which may be pressured by market volatility.
Charles Schwab's business model is well-diversified, spanning brokerage, banking, and wealth management services, allowing it to capture growth across different segments. The bank's focus on low-cost trading, investment advisory services, and a broad range of financial products gives it a competitive advantage in attracting retail and institutional clients. 
In addition, Schwab's vast network of individual retirement accounts (IRAs) and retail brokerage accounts positions it well to benefit from the long-term shift toward self-directed retirement savings.
Read Also: <a href="https://www.benzinga.com/news/24/10/41288103/elon-musks-fully-autonomous-driving-dreams-now-scheduled-for-2025-but-regulatory-hurdles-stand-in-th">Elon Musk&#8217;s Fully Autonomous Driving Dreams Now Scheduled For 2025, But Regulatory Hurdles Stand In The Way Of Tesla&#8217;s Robotaxi Rollout</a>
<h2 class="wp-block-heading">How To Buy SCHW Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Charles Schwab&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SCHW has a 52-week high of $79.49 and a 52-week low of $48.66.

SCHW

Why Charles Schwab (SCHW) Stock Is Rising

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Lexicon Pharmaceuticals, Mesoblast, Ventyx Biosciences among healthcare movers

Immuron ADR (IMRN) is near the bottom in its sector according to InvestorsObserver.IMRN gets an overall rating of 0. That means it scores higher than 0% of stocks.Immuron ADR gets a 0 rank in the Healthcare sector. Healthcare is number 1 out of 11 sectors. IMRN has an Overall Score of 0. Find out what this means to you and

Will Immuron ADR (IMRN) Trail the Rest of the Stocks in the Healthcare Sector?

ELTK, PSTX and LTRN among mid-day movers

Immuron gains after Travelan sales update

Immuron to raise up to $2M as part of an ATM equity offering

Immuron (IMRN) has released an update. Immuron Limited's CEO, Steven Lydeamore, is set to present at the Sharewise conference on July 9, 2024, disc...

Immuron CEO to Unveil Company Progress at Sharewise

Immuron (IMRN) has released an update. Immuron Limited has announced a significant surge in global sales of its Travelan&#xAE; product, with a record in...

Immuron's Travelan® Hits Record Global Sales

Immuron (IMRN) has released an update. Immuron Limited reported a significant increase in revenue, up 171.7% to $4.9 million for the year ended Jun...

Immuron Sees Revenue Surge Amid Higher R&D Costs

Immuron (IMRN) has disclosed a new risk, in the Accounting & Financial Operations category. Immuron faces a substantial business risk if it fails t...

Immuron's Compliance Crucial: Sarbanes-Oxley Act Adherence Key to Financial Stability and Investor Trust

AIMD

AMIX

APVO

BALY

CASI

CERO

ELTK

ENCP

GRPH

GRYP

IMRN

JFBR

JRVR

LBBB

LTRN

LXRX

MEDS

MESO

MRAI

PSTX

TCBP

VTYX

Press Releases

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Health Care

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Comments

Immuron

Noticias

Últimas noticias sobre Immuron (NASDAQ:IMRN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL